Trial Profile
An open-label, single arm study to provide access to fingolimod to MS patients who completed fingolimod phase IIIb studies and who benefited from treatment with fingolimod or do not have suitable alternative treatment options, but do not have access to the reimbursed drug
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Aug 2014
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 03 Jul 2014 According to the European Clinical Trials Database record, status changed from recruiting to discontinued.
- 16 Jul 2013 New trial record